Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by StockNews.com

Stock analysts at StockNews.com began coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note issued to investors on Tuesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Several other equities analysts also recently commented on MRNS. Jefferies Financial Group reaffirmed a “hold” rating and set a $0.50 price objective (down from $5.00) on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. Oppenheimer raised Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price target on the stock in a research note on Monday, September 23rd. EF Hutton Acquisition Co. I upgraded shares of Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. JMP Securities restated a “market perform” rating on shares of Marinus Pharmaceuticals in a report on Thursday, October 24th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $4.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. Nine equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $4.79.

Marinus Pharmaceuticals Stock Performance

MRNS opened at $0.32 on Tuesday. Marinus Pharmaceuticals has a 12 month low of $0.26 and a 12 month high of $11.26. The business’s 50-day moving average price is $1.08 and its 200-day moving average price is $1.26. The company has a market cap of $17.87 million, a P/E ratio of -0.13 and a beta of 1.26.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Suvretta Capital Management LLC boosted its stake in shares of Marinus Pharmaceuticals by 32.8% during the 3rd quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock worth $8,930,000 after acquiring an additional 1,253,901 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Marinus Pharmaceuticals by 5.0% in the first quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock worth $25,366,000 after acquiring an additional 132,689 shares during the period. abrdn plc lifted its holdings in Marinus Pharmaceuticals by 146.1% in the 3rd quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock worth $4,679,000 after purchasing an additional 1,578,329 shares in the last quarter. GSA Capital Partners LLP boosted its position in shares of Marinus Pharmaceuticals by 409.4% during the third quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock worth $1,789,000 after acquiring an additional 817,050 shares during the last quarter. Finally, Acadian Asset Management LLC bought a new position in shares of Marinus Pharmaceuticals during the 2nd quarter valued at about $813,000. Hedge funds and other institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.